Gene Therapy Targets Huntington's Disease Mechanism

Latus Bio researchers report that lowering MSH3 protein levels in brain cells slowed disease progression in preclinical models.

Updated on Nov. 8, 2026 in Biotech

Flat-color editorial illustration of a glass vial of amber liquid beside a steel pipette tip and clear tubing on a navy and cream field. — Latus Bio researchers reported that lowering levels of the DNA repair protein MSH3 slowed Huntington's disease progression in preclinical models. AI Illustration. Upload story photo >

Live Poll

Should the government fund gene therapy research for inherited diseases like Huntington's?

Latus Bio Inc. published research in Nature Communications supporting a gene therapy approach for Huntington's disease that reduces expression of the DNA repair protein MSH3. In nonhuman primates, the investigational treatment LTS-201 lowered MSH3 messenger RNA levels by 48% to 94%, depending on the dose.

Why it matters

Somatic instability, the process in which inherited DNA repeat sequences expand within cells over time, is increasingly implicated in Huntington's disease onset and progression. The findings suggest targeting this mechanism directly could offer a new therapeutic route for a currently untreatable inherited condition.

Preclinical results show MSH3 mRNA reductions of 48% to 94% in nonhuman primates, with more than 90% of medium spiny neurons examined showing reduction. The computational model's predicted change in clinical decline, ranging from about 50% to more than 120% versus natural history, has not been validated in human trials.

The players

Latus Bio Inc.

A Philadelphia-based biotechnology company developing gene therapies, including the investigational treatment LTS-201 for Huntington's disease.

Beverly L. Davidson

A geneticist who co-led the study and chairs Latus Bio's scientific advisory board, and who has published extensively on adeno-associated virus gene delivery for neurological disease.

The details

The study combined human disease progression data, computational modeling and animal experiments to evaluate lowering MSH3 expression. LTS-201 uses an engineered adeno-associated virus called AAV-DB-3 to deliver an artificial microRNA into medium spiny neurons in the striatum and projection neurons in the cerebral cortex.

• November 8, 2026: Latus Bio's research on the MSH3-targeting approach was published in Nature Communications.

Big Picture

The study builds on previously published work describing the AAV-DB-3 delivery system, extending that brain-targeting viral vector approach from prior applications to lowering MSH3 in Huntington's disease. It shifts emphasis from the huntingtin protein alone toward somatic instability as a therapeutic target.

For people with Huntington's disease or families affected by it, the research signals a possible future treatment direction, but no therapy is available yet based on these findings. The treatment remains preclinical, so any clinical use would require human trials to establish safety and effectiveness.

The takeaway

Targeting the cellular process of somatic instability offers a complementary route beyond lowering huntingtin protein itself. Readers tracking Huntington's research should watch for whether preclinical results advance into human clinical testing.